NorthWest Biotherapeutics Inc (NWBO)

[Poor Man -]

What kind of M.D. would involve himself in writing such a paper? That is so unethical, so slimy. This "rule" depends heavily on the assumption that clinical data leaks dominate the biotech investment landscape. It also ignores the possibility of un-natural SP manipulation, yet that appears to be what Feuerstein is all about.

That's such a nonsensical thesis by the folks at TheStreet, it's not surprising that AF and Cramer are so often wrong. See latest on Celldex that had a market cap of over $3 billion while in late phase III trials, only to crash and burn. Since the thesis is based on insider information propelling or hindering a biotech's stock price, then CLDX should have been a slam dunk for approval.

Truth of the matter is that stock prices, especially for small cap biotechs are impacted by an array of factors, not the least of which are market corrections and the aforementioned manipulation, that trying to make a prediction based on that kind of theory is just an amateur's approach - might as well use tarot cards.

Poor Man's thesis is that when a small biotech attracts the attention and efforts by an online publication like TheStreet, and sophisticated efforts are made to bash the company and its management through anonymous websites, the company must have meaningful upside value...otherwise, why bother?

I will also add that in my opinion management does not know how to manage or defend a public company, which has made matter's far worse for the stock price than it otherwise might be. But that doesn't change whether or not the FDA will approve L, which I believe there's a highly likelihood that they will.